

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 June 2018 (07.06.2018)



(10) International Publication Number
WO 2018/102427 A1

(51) International Patent Classification:

C07D 307/92 (2006.01) C07C 251/16 (2006.01)

(21) International Application Number:

PCT/US2017/063734

(22) International Filing Date:

29 November 2017 (29.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/427,441 29 November 2016 (29.11.2016) US

(71) Applicant: **BOSTON BIOMEDICAL, INC.** [US/US];
640 Memorial Drive, Cambridge, MA 02139 (US).

(72) Inventors; and

(71) Applicants: **ARUMUGASAMY, Jeevanandam**
[US/US]; 88 Joyce Lane, Boxborough, MA 01719 (US). **LL, Wei** [US/US]; 19 Black Oak Road, Wayland, MA 01778 (US).

(74) Agent: **MACALPINE, Jill, K.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, DC 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NAPHTHOFURAN DERIVATIVES, PREPARATION, AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are methods of preparation of I by reacting i with acid where R₁ and R₂ are each independently a leaving group. Intermediates to make i are also claimed.



WO 2018/102427 A1

**NAPHTHOFURAN DERIVATIVES, PREPARATION, AND METHODS OF
USE THEREOF**

[0001] The present application claims the benefit of priority of U.S. Provisional Application No. 62/427,441, filed November 29, 2016, which is incorporated herein by reference.

[0002] Cancer fatalities in the United States alone number in the hundreds of thousands each year. Despite advances in the treatment of certain forms of cancer through surgery, radiotherapy, and chemotherapy, many types of cancer are essentially incurable. Even when an effective treatment is available for a particular cancer, the side effects of such treatment can be severe and result in a significant decrease in quality of life. Most conventional chemotherapy agents have toxicity and limited efficacy, particularly for patients with advanced solid tumors. Chemotherapeutic agents cause damage to non-cancerous as well as cancerous cells. The therapeutic index of such compounds (a measure of the ability of the therapy to discriminate between cancerous and normal cells) can be quite low. Frequently, a dose of a chemotherapy drug that is effective to kill cancer cells will also kill normal cells, especially those normal cells (such as epithelial cells) which undergo frequent cell division. When normal cells are affected by the therapy, side effects such as hair loss, suppression of hematopoiesis, and nausea can occur. Depending on the general health of a patient, such side effects can preclude the administration of chemotherapy, or, at least, be extremely unpleasant and uncomfortable for the patient and severely decrease quality of the life of cancer patients. Even for cancer patients who respond to chemotherapy with tumor regression, such tumor response often is not accompanied by prolongation of

progression-free survival (PFS) or prolongation of overall survival (OS). As a matter of fact, cancer often quickly progress and form more metastasis after initial response to chemotherapy. Such recurrent cancers become highly resistant or refractory to chemotherapeutics.


[0003] Recent studies have uncovered the presence of cancer stem cells (CSC, also called tumor initiating cells or cancer stem-like cells) which have self-renewal capability and are considered to be fundamentally responsible for malignant growth, relapse and metastasis. Importantly, CSCs are inherently resistant to conventional therapies. Therefore, a targeted agent with activity against cancer stem cells holds a great promise for cancer patients.

[0004] STAT3 is an oncogene which is activated in response to cytokines and/or growth factors to promote proliferation, survival, and other biological processes. STAT3 is activated by phosphorylation of a critical tyrosine residue mediated by growth factor receptor tyrosine kinases, Janus kinases, or the Src family kinases. Upon tyrosine phosphorylation, STAT3 forms homo-dimers and translocates to the nucleus, binds to specific DNA-response elements in target gene promoters, and induces gene expression. STAT3 activates genes involved in tumorigenesis, invasion, and metastasis, including Bcl-x1, Akt, c-Myc, cyclin D1, VEGF, and survivin. STAT3 is aberrantly active in a wide variety of human cancers, including all the major carcinomas as well as some hematologic tumors. Persistently active STAT3 occurs in more than half of breast and lung cancers, colorectal cancers, ovarian cancers, hepatocellular carcinomas, and multiple myelomas, etc; and more than 95% of head/neck cancers. STAT3 is considered to be one of the major

mechanisms for drug resistance of cancer cells. However, STAT3 has proven a difficult target for discovering pharmaceutical inhibitor.

[0005] PCT Patent Application Publication Numbers WO2009036099, WO2009036101, WO2011116398, and WO2011116399 disclose that certain naphthofuran compounds have been shown to target cancer stem cells, inhibit non-stem cancer cells through inhibiting STAT3, and have the capability of killing many different types of cancer cells without causing damage to normal cells under certain exposure conditions. Accordingly, these naphthofuran compounds can be used for cancer treatment, especially for the treatment and prevention of refractory, recurrent, metastatic cancers, or STAT3-expressing cancers. The publications also describe certain processes for preparing naphthofuran compounds, derivatives, and intermediates thereof, and the pharmaceutical composition of relevant compounds. WO2009036099, WO2009036101, WO2011116398, and WO2011116399 are each incorporated herein by reference in their entirety.


[0006] For example, one of the naphthofuran compounds disclosed in these patent applications is one having formula (I):



prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.

[0007] Compounds having formula (I) may also be known as 2-acetylnaphtho[2,3-b]furan-4,9-dione, napabucasin, BBI-608, or BBI608, and they include tautomers thereof.

[0008] One aspect of the present disclosure relates to methods of preparing compounds having formula (I). In certain embodiments, the method comprises reacting a compound having formula (i):




i

salts and solvates thereof,

with an acid;

wherein R₁ and R₂ each independently is a leaving group.

[0009] In certain embodiments, the method comprises reacting a compound chosen from dihydronaphthofuran derivatives having formula (i-a):




i-a

salts and solvates thereof, with

an acid.

[0010] In certain embodiments, the method comprises reacting a compound having formula (ii):



ii

salts and solvates thereof;

wherein X is O or N-R₄, and

R₃ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups;

wherein R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, C(=O)R_g, S(=O)₂R_e, P(=O)₂R_e, C(=O)OR_e, C(=O)NR_bR_c, S(=O)₂NR_bR_c, and P(=O)₂NR_bR_c;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,


or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl

groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0011] In certain embodiments, the method comprises reacting a compound having formula (ii-a):



ii-a

salts and solvates thereof, wherein

R₃ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, and R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted


heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0012] In certain embodiments, the method comprises reacting a compound having formula (ii-b):



ii-b

salts and solvates thereof,

wherein R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,


or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups,

alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and


R_9 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0013] In certain embodiments, the method comprises reacting a compound having formula (ii-c):



salts and solvates thereof.

[0014] In certain embodiments, the method comprises reacting a compound having formula (ii-d):



salts and solvates thereof, wherein R_2 is a leaving group, and

R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;


wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups,


alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0015] In certain embodiments, the method comprises reacting a compound having formula (ii-e):



salts and solvates thereof, wherein R_2 is a leaving group.


[0016] In certain embodiments, the method comprises reacting a compound having formula (ii-f):



salts and solvates thereof,

wherein R_3 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.


[0017] In certain embodiments, the method comprises reacting a compound having formula (ii-g):



ii-g

salts and solvates thereof.


[0018] In certain embodiments, the method comprises reacting a compound having formula (ii-h):



ii-h

salts and solvates thereof, wherein R₂ is a leaving group.

[0019] In certain embodiments, the method comprises reacting a compound having formula (ii-i):



ii-i


salts and solvates thereof.

[0020] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii):




iii

[0021] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-a):



iii-a.


[0022] In certain embodiments, the method comprises converting a 2-hydroxynaphthalene-1,4-dione having formula (iv):



iv

salts and solvates thereof,
to a compound having formula (ii).

[0023] In certain embodiments, the method comprises reacting a 2-hydroxynaphthalene-1,4-dione having formula (iv) with a compound of formula (v):



v

wherein R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups,


cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,

or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_f and R_g each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, or substituted aryl groups.


[0024] Another aspect of the present disclosure relates to certain compounds that can be used to prepare compounds having formula (I). In certain embodiments, provided herein is a compound having formula (i):



salts and solvates thereof;


wherein R_1 and R_2 each independently is a leaving group.

[0025] In certain embodiments, provided herein is a compound having formula (i-a):



salts and solvates thereof.

[0026] In certain embodiments, provided herein is a compound having formula (ii):



salts and solvates thereof;

wherein X is O or N- R_4 , and

R_3 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups;

wherein R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups,

$C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$,
 $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;


wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,

or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0027] In certain embodiments, provided herein is a compound having formula (ii-a):



salts and solvates thereof,

wherein R_3 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, and R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;


wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,

or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0028] In certain embodiments, provided herein is a compound formula (ii-b):



ii-b

salts and solvates thereof,

wherein R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups,

heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,


or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted


heterocycle groups, aryl groups, and substituted aryl groups.

[0029] In certain embodiments, provided herein is a compound having formula (ii-c):



salts and solvates thereof.

[0030] In certain embodiments, provided herein is a compound having formula (ii-d):



salts and solvates thereof, wherein R_2 is a leaving group, and

R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, or $P(=O)_2NR_bR_c$;


wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl

groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.


[0031] In certain embodiments, provided herein is a compound having formula (ii-e):



ii-e

salts and solvates thereof, wherein R_2 is a leaving group.


[0032] In certain embodiments, provided herein is a compound having formula (ii-f):



salts and solvates thereof,


wherein R₃ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0033] In certain embodiments, provided herein is a compound having formula (ii-g):




salts and solvates thereof.

[0034] In certain embodiments, provided herein is a compound having formula (ii-h):



salts and solvates thereof, wherein R₂ is a leaving group.

[0035] In certain embodiments, provided herein is a compound having formula (ii-i):



salts and solvates thereof.

[0036] Features and advantages of the present disclosure may be more readily understood by those of ordinary skill in the art upon reading the following detailed description. It is to be appreciated that certain features of the present disclosure that are, for clarity reasons, described above and below in the context of separate embodiments, may also be combined to form a single embodiment and that some features of the present disclosure that are, for brevity reasons, described in the context of a single embodiment, may also be combined so as to form sub-combinations thereof. Embodiments identified herein as exemplary are intended to be illustrative and not limiting.

[0037] Unless specifically stated otherwise, references made in the singular may also include the plural. For example, "a" and "an" may refer to either one, or one or more.

[0038] When a range of values is listed herein, it is intended to encompass each value and sub-range within that range. For example, "C₁₋₆ alkyl" is intended to encompass C₁, C₂, C₃, C₄, C₅, C₆, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆, C₂₋₅, C₂₋₄, C₂₋₃, C₃₋₆, C₃₋₅, C₃₋₄, C₄₋₆, C₄₋₅, and C₅₋₆ alkyl.

Similarly, "1-5 mg" is intended to encompass 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 1-2 mg, 1-3 mg, 1-4 mg, 1-5 mg, 2-3 mg, 2-4 mg, 2-5 mg, 3-4 mg, 3-5 mg, and 4-5 mg.

[0039] When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below those numerical values. In general, the term "about" is used herein to modify a

numerical value above and below the stated value by a variance of 20%, 10%, 5%, or 1%. In certain embodiments, the term "about" is used to modify a numerical value above and below the stated value by a variance of 10%. In certain embodiments, the term "about" is used to modify a numerical value above and below the stated value by a variance of 5%. In certain embodiments, the term "about" is used to modify a numerical value above and below the stated value by a variance of 1%.

[0040] Definitions of specific functional groups and chemical terms are described in more detail below. General principles of organic chemistry, as well as specific functional moieties and reactivity, are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 2006.

[0041] As used herein, the term "C_x-C_y" refers in general to groups that have from x to y (inclusive) carbon atoms. Therefore, for example, C₁-C₆ refers to groups that have 1, 2, 3, 4, 5, or 6 carbon atoms, which encompass C₁-C₂, C₁-C₃, C₁-C₄, C₁-C₅, C₂-C₃, C₂-C₄, C₂-C₅, C₂-C₆, and all like combinations. "C₁-C₂₀" and the likes similarly encompass the some combinations between 1 and 20 (inclusive) carbon atoms, such as C₁-C₆, C₁-C₁₂, and C₃-C₁₂.

[0042] As used herein, the term "alkyl" group refers to a straight or branched chain alkane (hydrocarbon) radical. For example, the term "alkyl" group can include a C₁-C₂₀ alkyl, a C₁-C₁₂ alkyl, or a C₁-C₆ alkyl. Non-limiting examples of "alkyl" groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, and dodecyl. "Substituted alkyl" group refers to an alkyl group substituted with one or more substituents, such as 1 to 4

substituents, at any available point of attachment. Non-limiting examples of substituents include halogen, cyano, nitro, CF_3 , OCF_3 , cycloalkyl groups, alkenyl groups, cycloalkenyl groups, alkynyl groups, heterocycle groups, aryl groups, OR_a , $S(=O)R_e$, $S(=O)_2R_e$, $P(=O)_2R_e$, $S(=O)_2OR_e$, $P(=O)_2OR_e$, $NR_bR_cNR_bS(=O)_2R_e$, $NR_bP(=O)_2R_e$, $S(=O)_2NR_bR_c$, $P(=O)_2NR_bR_c$, $C(=O)OR_d$, $C(=O)R_a$, $C(=O)NR_bR_c$, $OC(=O)R_a$, $OC(=O)NR_bR_c$, $NR_bC(=O)OR_e$, $NR_dC(=O)NR_bR_c$, $NR_dS(=O)_2NR_bR_c$, $NR_dP(=O)_2NR_bR_c$, $NR_bC(=O)R_a$, and $NR_bP(=O)_2R_e$, wherein R_a is chosen from hydrogen, alkyl groups, cycloalkyl groups, alkenyl groups, cycloalkenyl groups, alkynyl groups, heterocycle groups, and aryl groups; R_b , R_c , and R_d are independently chosen from hydrogen, alkyl groups, cycloalkyl groups, heterocycle groups, and aryl groups, or R_b and R_c together with the N to which they are bonded form an optionally substituted heterocycle group; and R_e is chosen from alkyl groups, cycloalkyl groups, alkenyl groups, cycloalkenyl groups, alkynyl groups, heterocycle groups, and aryl groups. In the aforementioned exemplary substituents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle, and aryl are themselves optionally substituted.

[0043] As used herein, the term "alkenyl" group refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond. For example, the term "alkenyl" group can include a C_2 - C_{20} alkenyl, a C_2 - C_{12} alkenyl, or a C_2 - C_6 alkenyl. Non-limiting examples of such groups include ethenyl or allyl. "Substituted alkenyl" group refers to an alkenyl group substituted with one or more substituents, such as 1 to 4 substituents, at any available point of attachment. Non-limiting examples of substituents include alkyl groups, substituted alkyl groups, as well as those groups recited above as exemplary

alkyl substituents. The exemplary substituents are themselves optionally substituted.

[0044] As used herein, the term "alkynyl" group refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond. For example, the term "alkynyl" group can include a C₂-C₂₀ alkynyl, a C₂-C₁₂ alkynyl, or a C₂-C₆ alkynyl. A non-limiting example of such groups is ethynyl. "Substituted alkynyl" group refers to an alkynyl group substituted with one or more substituents, such as 1 to 4 substituents, at any available point of attachment. Non-limiting examples of substituents include alkyl groups, substituted alkyl groups, as well as those groups recited above as exemplary alkyl substituents. The exemplary substituents are themselves optionally substituted.

[0045] As used herein, the term "aryl" group refers to cyclic, aromatic hydrocarbon groups that have 1 to 5 aromatic rings, such as monocyclic or bicyclic aromatic rings such as phenyl, biphenyl, or naphthyl. Where an aryl group contains two or more aromatic rings, those aromatic rings may be joined at a single point (e.g., biphenyl) or may be fused (e.g., naphthyl, phenanthrenyl and the like). "Substituted aryl" group refers to an aryl group substituted by one or more substituents, such as 1 to 3 substituents, at any point of attachment. Non-limiting examples of substituents include nitro, cycloalkyl groups, cycloalkenyl groups, cyano, alkyl, as well as those groups recited above as exemplary alkyl substituents. The exemplary substituents are themselves optionally substituted. Non-limiting examples of substituents also include fused cyclic groups, for example fused cycloalkyl groups, fused cycloalkenyl groups, fused heterocycle groups, and fused aryl groups, where the aforementioned

cycloalkyl, cycloalkenyl, heterocycle, and aryl group substituents are themselves optionally substituted.

[0046] As used herein, the term "cycloalkyl" group refers to a fully saturated cyclic hydrocarbon group having 1 to 4 rings and 3 to 8 carbons per ring. Non-limiting examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. "Substituted cycloalkyl" group refers to a cycloalkyl group substituted with one or more substituents, such as 1 to 4 substituents, at any available point of attachment. Non-limiting examples of substituents include nitro, cyano, alkyl, substituted alkyl, as well as those groups recited above as exemplary alkyl substituents. The exemplary substituents are themselves optionally substituted. Non-limiting examples of substituents also include spiro-attached or fused cyclic substituents, such as spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents are themselves optionally substituted.

[0047] As used herein, the term "cycloalkenyl" group refers to a partially unsaturated cyclic hydrocarbon group containing 1 to 4 rings and 3 to 8 carbons per ring. Non-limiting examples of such groups include cyclobutenyl, cyclopentenyl, and cyclohexenyl. "Substituted cycloalkenyl" refers to a cycloalkenyl group substituted with one more substituents, such as 1 to 4 substituents, at any available point of attachment. Non-limiting examples of substituents include nitro, cyano, alkyl groups, as well as those groups recited above as exemplary alkyl substituents. The exemplary substituents are themselves optionally substituted. Non-limiting examples of substituents also

include spiro-attached or fused cyclic substituents, such as spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents are themselves optionally substituted.

[0048] The term "carbocyclic" group refers to aromatic or non-aromatic 3 to 7 membered monocyclic, 7 to 11 membered bicyclic, and 8 to 16 membered tricyclic groups, in which all atoms of the ring or rings are carbon atoms. "Substituted carbocyclic" group refers to a carbocyclic group substituted with one or more substituents, such as 1 to 4 substituents, at any available point of attachment. Non-limiting examples of substituents include nitro, cyano, OR_a, wherein R_a is as defined hereinabove, as well as those groups recited above as exemplary cycloalkyl substituents. The exemplary substituents are themselves optionally substituted.

[0049] As used herein, the terms "heterocycle" and "heterocyclic" groups refer to fully saturated, or partially or fully unsaturated, including aromatic (i.e., "heteroaryl") cyclic groups (for example, 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 8 to 16 membered tricyclic ring systems) that have at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3, or 4 heteroatoms selected from nitrogen atoms, oxygen atoms, and/or sulfur atoms, where the nitrogen and sulfur heteroatoms are optionally oxidized and the nitrogen heteroatoms are optionally quaternized. The term "heteroarylium" refers to a heteroaryl group bearing a quaternary nitrogen atom and thus a positive charge. The

heterocyclic group may be attached to the remainder of the molecule at any heteroatom or carbon atom of the ring or ring system. Non-limiting examples of monocyclic heterocyclic groups include azetidiny, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazoliny, imidazolidiny, oxazolyl, oxazolidiny, isoxazoliny, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidiny, isothiazolyl, isothiazolidiny, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidiny, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidiny, 2-oxopyrrolodiny, 2-oxoazepiny, azepiny, hexahydrodiazepiny, 4-piperidonyl, pyridyl, pyraziny, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl, and the like. Exemplary bicyclic heterocyclic groups include indolyl, isoindolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzothienyl, benzo[d][1,3]dioxolyl, 2,3-dihydrobenzo[b][1,4]dioxiny, quinuclidiny, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indoliziny, benzofuryl, benzofurazanyl, chromonyl, coumariny, benzopyranyl, cinnolinyl, quinoxaliny, indazolyl, pyrrolopyridyl, furopyridiny (such as furo[2,3-c]pyridiny, furo[3,2-b]pyridiny] or furo[2,3-b]pyridiny), dihydroisoindolyl, dihydroquinazoliny (such as 3,4-dihydro-4-oxoquinazoliny), triazinylazepiny, and tetrahydroquinolinyl. Non-limiting examples of tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthroliny, acridiny, phenanthridiny, and xanthenyl.

[0050] As used herein, "substituted heterocycle" and "substituted heterocyclic" (such as "substituted

heteroaryl") groups refer to heterocycle or heterocyclic groups substituted with one or more substituents, such as 1 to 4 substituents, at any available point of attachment. Non-limiting examples of substituents include cycloalkyl groups, cycloalkenyl groups, nitro, oxo (i.e., =O), cyano, alkyl, as well as those groups recited above as exemplary alkyl substituents. The exemplary substituents are themselves optionally substituted. Non-limiting examples of substituents also include spiro-attached or fused cyclic substituents at any available point or points of attachment, such as spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents are themselves optionally substituted.

[0051] As used herein, the term "halogen" includes fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

[0052] It will be appreciated that the compounds, as described herein, may be substituted with any number of substituents or functional moieties. Throughout the disclosure, groups and substituents thereof may be chosen to provide stable moieties and compounds. Unless otherwise indicated, any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.

[0053] Certain compounds of the present disclosure may exist in particular geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the present disclosure. Additional

asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in the present disclosure.

[0054] Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present disclosure. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present disclosure. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.

[0055] If, for instance, a particular enantiomer of a compound of the present disclosure is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.

[0056] One of ordinary skill in the art will appreciate that synthetic methods, as described herein, may utilize a variety of protecting groups. By the term "protecting group", as used herein, it is meant that a particular functional moiety, e.g., O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound. In

certain embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group should be selectively removable in good yield by non-toxic reagents that do not attack the other functional groups and that may be readily available; the protecting group forms an easily separable derivative (in certain embodiments, without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction. Oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized. Non-limiting examples of protecting groups can be found in *Protective Groups in Organic Synthesis*, Third Ed. Greene, T. W. and Wuts, P. G., Eds., John Wiley & Sons, New York: 1999.

[0057] As used herein, the term "leaving group" refers to a group that can be substituted by another group in a substitution reaction or that can be removed in an elimination reaction (e.g., an electronic cascade reaction or a spirocyclization reaction). Within either of these categorical definitions exemplary leaving groups include, but are not limited to, H, an halide (fluoride, chloride, bromide, and iodide), an azide, a sulfonate (e.g., an optionally substituted C₁-C₆ alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C₇-C₁₂ alkylbenzenesulfonate, such as p-toluenesulfonate), succinimide-N-oxide, p-nitrophenoxide, pentafluorophenoxide, tetrafluorophenoxide, OR_a, NR_bR_c, a carboxylate, an aminocarboxylate (carbamate), and an alkoxy-carboxylate (carbonate); where R_a is chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, alkynyl groups,

substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and R_b and R_c each is independently chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group. In certain embodiments satisfying one definition given above, the leaving group is H. In other certain embodiments, the leaving group is chosen from halides (fluoride, chloride, bromide, and iodide). In certain embodiments, the leaving group is chosen from sulfonates (e.g., an optionally substituted C_1 - C_6 alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C_7 - C_{12} alkylbenzenesulfonate, such as p-toluenesulfonate). In certain embodiments, the leaving group is chosen from succinimide-N-oxide, p-nitrophenoxide, and pentafluorophenoxide, tetrafluorophenoxide. In certain embodiments, the leaving group is an azide. In certain embodiments, the leaving group is chosen from aminocarboxylates (carbamates). In certain embodiments, the leaving group is chosen from carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxy-carboxylates (e.g., methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, or tert-butoxycarboxylate), and aryloxy-carboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, the leaving group is chosen from OR_a and NR_bR_c , where R_a is chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups,

alkynyl groups, substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and R_b and R_c each is independently chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, or substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group.

[0058] Compounds of the present disclosure may, subsequent to their preparation, be isolated and/or purified to obtain a composition containing an amount by weight equal to or greater than 90% ("substantially pure"), which may then be used and/or formulated as described herein. In certain embodiments, the compounds of the present disclosure are more than 95% pure. In certain embodiments, the compounds of the present disclosure are more than 99% pure.

[0059] As used herein, a solid form of the present disclosure is "substantially pure" when it accounts for an amount by weight equal to or greater than 90% of the sum of all solid form(s) in a sample as determined by a method in accordance with the art, such as quantitative XRPD. In certain embodiments, the solid form is "substantially pure" when it accounts for an amount by weight equal to or greater than 95% of the sum of all solid form(s) in a sample. In certain embodiments, the solid form is "substantially pure" when it accounts for an amount by weight equal to or greater than 99% of the sum of all solid form(s) in a sample.

[0060] Solvates of the compounds of the present disclosure are also contemplated herein. The term "solvate" refers to an aggregate that comprises one or more molecules

of a compound of the present disclosure and one or more molecules of a solvent or solvents, such as in fixed stoichiometric ratios. Solvates of the compounds of the present disclosure include, for example, hydrates.

[0061] As used herein, the term "solid form" or "Form" refers to a crystal form and/or amorphous form of a solid material.

[0062] As used herein, the terms "crystal form" and "crystalline form" can be used interchangeably to denote polymorphs and pseudo-polymorphs of a crystalline solid.

[0063] As used herein, the term "polymorph" refers to a crystal structure in which a compound can crystallize. Different polymorphs have different molecular packing arrangements in the crystal lattice but all share the same chemical composition.

[0064] Crystal forms can be identified and distinguished from each other by one or more analytical tests and/or physical properties such as, for example, X-ray powder diffraction (XRPD), single crystal X-ray diffraction, differential scanning calorimetry (DSC), dynamic vapor sorption (DVS), and/or thermogravimetric analysis (TGA).

[0065] As used herein, the term "polymorphism" denotes the ability of a compound to form more than one polymorph.

[0066] As used herein, the terms "solvate" and "pseudo-polymorph" can be used interchangeably to denote a crystal having either stoichiometric or nonstoichiometric amounts of a solvent incorporated in the crystal lattice. If the incorporated solvent is water, the solvate formed is a "hydrate". When the incorporated solvent is alcohol, the solvate formed is an "alcoholate".

[0067] As used herein, a "metastable" form is a crystal form which does not have the highest rank order of thermodynamic stability.

[0068] As used herein, the term "amorphous form" denotes a solid material which does not possess a distinguishable crystal lattice and the molecular arrangement of molecules lacks a long-range order. In particular, amorphous denotes a material that does not show any sharp Bragg diffraction peak.

[0069] As used herein, the term "X-ray powder diffraction pattern" or "XRPD pattern" refers to an experimentally obtained diffractogram. X-ray powder diffraction patterns plot peak positions (abscissa) versus peak intensities (ordinate).

[0070] As used herein, the term "XRPD" refer to the analytical method of X-Ray Powder Diffraction. XRPD patterns can be recorded at ambient conditions in transmission geometry with a diffractometer. For an amorphous material, an XRPD pattern may include one or more broad peaks; and for a crystalline material, an XRPD pattern may include one or more peaks, each identified by its angular value as measured in degrees 2θ . The repeatability of the angular values is in the range of $\pm 0.2^\circ 2\theta$, i.e., the angular value can be the angular value $+0.2^\circ$, the angular value -0.2° , or any value between those two end points (angular value $+0.2^\circ$ and angular value -0.2°).

[0071] As used herein, the term "DSC" refers to the analytical method of Differential Scanning calorimetry.

[0072] As used herein, the term "onset" refers to the intersection point of the baseline before transition and the inflection tangent.

[0073] As used herein, the term "glass transition temp" (T_g) refers to the temperature above which a glassy amorphous solid becomes rubbery.

[0074] As used herein, the term "TGA" refers to the analytical method of Thermo Gravimetric Analysis.

[0075] As used herein, the term "solvent" refers to any liquid in which the product is at least partially soluble (e.g., solubility of product >1 g/l).


[0076] As used herein, the term "acceptable" refers to being compatible with the other ingredients of the formulation and not injurious to the patient.

[0077] As used herein, the term "prodrug" refers to a pharmacological derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug. Such prodrugs then are pharmaceutically active *in vivo*, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds herein may be called single, double, triple, etc., depending on the number of biotransformation steps required to release the active drug within the organism, and the number of functionalities present in a precursor-type form.

[0078] Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism. Prodrugs commonly known in the art include well-known acid derivatives, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, amides prepared by reaction of the parent acid compound with an amine, basic groups reacted to form an acylated base derivative, etc. Other prodrug derivatives may be combined with other features disclosed herein to enhance bioavailability. Accordingly, those of skill in the art will appreciate that certain of the presently disclosed compounds having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds having an amino acid residue, or a polypeptide

chain of two or more (e.g., two, three, or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of the presently disclosed compounds. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds having a carbonate, carbamate, amide and/or alkyl ester moiety covalently bonded to any of the above substituents disclosed herein.

[0079] One aspect of the present disclosure relates to methods of making compounds having formula (I). In certain embodiments, the method comprises reacting a compound having formula (i)



salts and solvates thereof, with an acid; wherein R₁ and R₂ each independently is a leaving group.

[0080] In certain embodiments, the method comprises reacting a compound of formula (i) with an acid. In certain embodiments, the acid comprises an inorganic acid or an organic acid. In certain embodiments, the acid comprises an inorganic acid. In certain embodiments, the acid comprises an acid chosen from sulfuric acid (H₂SO₄), phosphoric acid (H₃PO₄), nitric acid (HNO₃), perchloric acid (HClO₄), hydrofluoric acid (HF), hydrochloric acid (HCl), hydrobromic acid (HBr), or hydroiodic acid (HI). In certain embodiments, the acid comprises

an acid chosen from sulfuric acid (H_2SO_4), phosphoric acid (H_3PO_4), or hydrochloric acid (HCl). In certain embodiments, the acid comprises sulfuric acid (H_2SO_4). In certain embodiments, the acid comprises phosphoric acid (H_3PO_4). In certain embodiments, the acid comprises hydrochloric acid (HCl).

[0081] In certain embodiments, the acid comprises an organic acid. In certain embodiments, the acid comprises an acid chosen from carboxylic acids and sulfonic acids, where each of the carboxylic acids and sulfonic acids optionally is substituted. In certain embodiments, the acid comprises an acid chosen from carboxylic acids, halocarboxylic acids, or anhydrides thereof. In certain embodiments, the acid comprises an acid chosen from formic acid, acetic acid, acetic anhydride, propionic acid, propionic anhydride, fluoroacetic acid, trifluoroacetic acid, trifluoroacetic anhydride, chloroacetic acid, chloroacetic anhydride, dichloroacetic acid, trichloroacetic acid, citric acid, gluconic acid, lactic acid, oxalic acid, tartaric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, polystyrenesulfonic acid, and ascorbic acid. In certain embodiments, the acid comprises an acid chosen from formic acid, acetic acid, acetic anhydride, trifluoroacetic acid, trifluoroacetic anhydride, chloroacetic acid, chloroacetic anhydride, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid. In certain embodiments, the acid comprises formic acid. In certain embodiments, the acid comprises acetic acid. In certain embodiments, the acid comprises acetic anhydride. In certain embodiments, the acid comprises trifluoroacetic acid. In certain embodiments, the acid comprises methanesulfonic acid.

[0082] In certain embodiments, the acid comprises an inorganic acid and an organic acid. In certain embodiments, the ratio of the inorganic acid to the organic acid is from about 0.1 to about 20, about 0.2 to about 10, about 0.5 to about 5, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.2, about 1.5, or about 2.

[0083] In certain embodiments, the method comprises reacting a solution of the compound (i) with an acid. In certain embodiments, the solution of compound (i) comprises a solvent chosen from protic solvents or aprotic solvents. In certain embodiments, the solution comprises a solvent chosen from water-miscible solvents and water-immiscible solvents. In certain embodiments, the solution comprises a solvent chosen from organic acids, alcohols, esters, amines, amides, aminoalcohols, ethers, sulfoxides, and heteroaromatics. In certain embodiments, the solution comprises a solvent chosen from acetone, acetonitrile, ethyl acetate, isopropyl acetate, dimethylformamide (DMF), N-methylpyrrolidone (NMP), dimethylimidazolidinone (DMI), dimethylsulfoxide (DMSO), dioxane, methanol, ethanol, propanol, iso-propanol, formic acid, acetic acid, propanoic acid, pyridine, and tetrahydrofuran. In certain embodiments, the solution comprises a solvent chosen from isopropyl acetate, dimethylformamide (DMF), N-methylpyrrolidone (NMP), or dimethylimidazolidinone (DMI). In certain embodiments, the solution comprises isopropyl acetate. In certain embodiments, the solution comprises dimethylformamide (DMF). In certain embodiments, the solution comprises N-methylpyrrolidone (NMP). In certain embodiments, the solution comprises dimethylimidazolidinone (DMI).

[0084] In certain embodiments, the ratio of the acid to the solution of the compound (i) is from about 0.1 to about

50, about 0.5 to about 20, about 1 to about 10, about 1 to about 5, about 1, about 2, about 3, or about 4.

[0085] In certain embodiments, the method comprises reacting the compound (i) with a base. In certain embodiments, the base comprises an inorganic base or an organic base. In certain embodiments, the base comprises a base chosen from LiOH, NaOH, KOH, Na₂CO₃, NaHCO₃, and ammonia.

[0086] In certain embodiments, the reaction comprises dissolving compound (i) in dimethylformamide (DMF). In certain embodiments, the reaction comprises adding the DMF solution into an acid mixture comprising sulfuric acid and acetic acid. In certain embodiments, the concentration of sulfuric acid in the acid mixture is from about 10% to about 90%, about 20% to about 80%, about 20%, about 30%, about 40%, about 50%, about 60%, or about 70%. In certain embodiments, the reaction temperature is from about 0°C to about 80°C. In certain embodiments, the reaction temperature is about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, about 40°C, or about 50°C. In certain embodiments, the reaction comprises mixing the reaction mixture with water.


[0087] In certain embodiments, R₁ is chosen from halides, OR_a, and NR_bR_c; where R_a is chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, alkynyl groups, substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and R_b and R_c each is independently chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted

heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group. In certain embodiments, R_1 is chosen from Cl, Br, I, OR_a , and NR_bR_c ; where R_a is chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and R_b and R_c each is independently chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R_1 is chosen from Cl, Br, I, and NR_bH ; where R_b is chosen from alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, aryl groups, and substituted aryl groups. In certain embodiments, R_1 is NR_bH , where R_b is phenyl or substituted phenyl.

[0088] In certain embodiments, R_2 is chosen from H, halides, sulfonates (e.g., an optionally substituted C_1 - C_6 alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C_7 - C_{12} alkylbenzenesulfonate, such as p-toluenesulfonate), an azide, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxy-carboxylates (e.g., methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, or tert-butoxy-carboxylate), and aroxy-carboxylates (e.g., phenoxy-carboxylate, methylphenoxy-carboxylate). In certain embodiments, R_2 is chosen from H, halides, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxy-carboxylates (e.g., methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, or tert-butoxy-carboxylate), or


aroxycarboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, R_2 is chosen from H, Cl, Br, I, $-COOH$, $-COO^-$, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, tert-butoxycarboxylate, phenoxycarboxylate, and methylphenoxycarboxylate. In certain embodiments, R_2 is chosen from H, Cl, Br, $-COOH$, $-COO^-$, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, and tert-butoxycarboxylate. In certain embodiments, R_2 is H. In certain embodiments, R_2 is tert-butoxycarboxylate.

[0089] In certain embodiments, the method comprises reacting a compound having formula (i-a):



salts and solvates thereof, with an acid.

[0090] In certain embodiments, the method comprises reacting a compound having formula (ii):



salts and solvates thereof;

wherein R_3 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, and

X is O or N-R₄;

wherein R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, C(=O)R_g, S(=O)₂R_e, P(=O)₂R_e, C(=O)OR_e, C(=O)NR_bR_c, S(=O)₂NR_bR_c, and P(=O)₂NR_bR_c;


wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl

groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0091] In certain embodiments, X is N-R₄. In certain embodiments, the method comprises reacting a compound having formula (ii-a):



salts and solvates thereof,

wherein R₃ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, and R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, C(=O)R_g, S(=O)₂R_e, P(=O)₂R_e, C(=O)OR_e, C(=O)NR_bR_c, S(=O)₂NR_bR_c, and P(=O)₂NR_bR_c;


wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups,

alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0092] In certain embodiments, R_3 is hydrogen. In certain embodiments, the method comprises reacting a compound having formula (ii-b):



salts and solvates thereof,

wherein R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups,


substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0093] In certain embodiments, R_4 is chosen from alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R_4 is chosen from alkyl groups, cycloalkyl groups, heterocycle groups, and aryl groups. In certain embodiments, R_4 is chosen from methyl, ethyl, isopropyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridyl, and pyrrolyl. In certain embodiments, R_4 is chosen from phenyl, pyridyl, and pyrrolyl. In certain embodiments, R_4 is phenyl.

[0094] In certain embodiments, R_4 is chosen from $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$; wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group; R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups,


aryl groups, and substituted aryl groups; and R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R_4 is $C(=O)R_g$, wherein R_g is chosen from alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, aryl groups, and substituted aryl groups. In certain embodiments, R_4 is $C(=O)R_g$, wherein R_g is chosen from methyl, ethyl, propyl, isopropyl, butyl, t-butyl, phenyl, and substituted phenyl. In certain embodiments, R_4 is $C(=O)OR_e$, wherein R_e is chosen from methyl, ethyl, propyl, isopropyl, butyl, t-butyl, phenyl, and substituted phenyl. In certain embodiments, R_4 is $S(=O)_2R_e$, wherein R_e is chosen from alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, aryl groups, and substituted aryl groups. In certain embodiments, R_4 is $S(=O)_2R_e$, wherein R_e is chosen from alkyl groups, perhaloalkyl groups, aryl groups, and substituted aryl groups. In certain embodiments, R_4 is chosen from methanesulfonate, trifluoromethanesulfonate, and p-toluenesulfonate.


[0095] In certain embodiments, the method comprises reacting a compound chosen from compounds having formula (ii-c):



salts and solvates thereof.

[0096] In certain embodiments, R_3 is a substituted alkyl

group. In certain embodiments, R_3 is , wherein R_2 is a leaving group. In certain embodiments, the method comprises reacting a compound chosen from compounds having formula (ii-d):



salts and solvates thereof, wherein R_2 is a leaving group, and

R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups,

substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and


R_g is hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0097] In certain embodiments, R₂ is chosen from H, halides, sulfonates (e.g., an optionally substituted C₁-C₆ alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C₇-C₁₂ alkylbenzenesulfonate, such as p-toluenesulfonate), an azide, carboxylates (e.g., -COOH or -COO⁻), alkoxy-carboxylates (e.g., methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, or tert-butoxy-carboxylate), and aryloxy-carboxylates (e.g., phenoxy-carboxylate, methylphenoxy-carboxylate). In certain embodiments, R₂ is chosen from H, halides, carboxylates

(e.g., -COOH or -COO⁻), alkoxy-carboxylates (e.g., methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, or tert-butoxy-carboxylate), and aryloxy-carboxylates (e.g., phenoxy-carboxylate, methylphenoxy-carboxylate). In certain embodiments, R₂ is chosen from H, Cl, Br, I, -COOH, -COO⁻, methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, tert-butoxy-carboxylate, phenoxy-carboxylate, and methylphenoxy-carboxylate. In certain embodiments, R₂ is chosen from H, Cl, Br, -COOH, -COO⁻, methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, and tert-butoxy-carboxylate. In certain embodiments, R₂ is H. In certain embodiments, R₂ is tert-butoxy-carboxylate.

[0098] In certain embodiments, R₄ is chosen from alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R₄ is chosen from alkyl groups, cycloalkyl groups, heterocycle groups, and aryl groups. In certain embodiments, R₄ is chosen from methyl, ethyl, isopropyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridyl, and pyrrolyl. In certain embodiments, R₄ is chosen from phenyl, pyridyl, and pyrrolyl. In certain embodiments, R₄ is phenyl.

[0099] In certain embodiments, the method comprises reacting a compound chosen from compounds having formula (ii-e):




ii-e

salts and solvates thereof, wherein R_2 is a leaving group.

[0100] In certain embodiments, R_2 is chosen from H, halides, sulfonates (e.g., an optionally substituted C_1 - C_6 alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C_7 - C_{12} alkylbenzenesulfonate, such as p- toluenesulfonate), an azide, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxycarboxylates (e.g., methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, or tert-butoxycarboxylate), and aroxy-carboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, R_2 is chosen from H, halides, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxycarboxylates (e.g., methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, or tert-butoxycarboxylate), and aroxy-carboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, R_2 is chosen from H, Cl, Br, I, $-COOH$, $-COO^-$, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, tert-butoxycarboxylate, phenoxycarboxylate, and methylphenoxycarboxylate. In certain embodiments, R_2 is chosen from H, Cl, Br, $-COOH$, $-COO^-$, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, and tert-butoxycarboxylate. In certain embodiments, R_2 is H. In certain embodiments, R_2 is tert-butoxycarboxylate.


[0101] In certain embodiments, X is O. In certain embodiments, the method comprises reacting a compound having formula (ii-f):



salts and solvates thereof,


wherein R₃ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.


[0102] In certain embodiments, R₃ is hydrogen. In certain embodiments, the method comprises reacting a compound having formula (ii-g):




salts and solvates thereof.

[0103] In certain embodiments, R₃ is chosen substituted alkyl




groups. In certain embodiments, R₃ is , wherein R₂ is a leaving group. In certain embodiments, the method comprises reacting a compound chosen from compounds having formula (ii-h):



salts and solvates thereof, wherein R_2 is a leaving group.


[0104] In certain embodiments, R_2 is chosen from H, halides, sulfonates (e.g., an optionally substituted C_1 - C_6 alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C_7 - C_{12} alkylbenzenesulfonate, such as p- toluenesulfonate), an azide, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxycarboxylates (e.g., methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, or tert-butoxycarboxylate), and aroxy-carboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, R_2 is chosen from H, halides, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxycarboxylates (e.g., methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, or tert-butoxycarboxylate), or aroxy-carboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, R_2 is chosen from H, Cl, Br, I, $-COOH$, $-COO^-$, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, tert-butoxycarboxylate, phenoxycarboxylate, and methylphenoxycarboxylate. In certain embodiments, R_2 is chosen from H, Cl, Br, $-COOH$, $-COO^-$, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, and tert-butoxycarboxylate. In certain embodiments, R_2 is H. In certain embodiments, R_2 is tert-butoxycarboxylate.

[0105] In certain embodiments, the method comprises reacting a compound chosen from compounds having formula (ii-i):



salts and solvates thereof.

[0106] In certain embodiments, the method comprises reacting the compound (ii) with a nucleophile. For example, the nucleophile can be a Michael donor. In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii):



wherein R_2 and R_5 each independently is a leaving group.

[0107] In certain embodiments, R_2 is chosen from H, halides, sulfonates (e.g., an optionally substituted C_1 - C_6 alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C_7 - C_{12} alkylbenzenesulfonate, such as p- toluenesulfonate), an azide, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxycarboxylates (e.g., methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, or tert-butoxycarboxylate), and aryloxycarboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, R_2 is chosen from H, halides, carboxylates (e.g., $-COOH$ or $-COO^-$), alkoxycarboxylates (e.g., methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, or tert-butoxycarboxylate), and aryloxycarboxylates (e.g., phenoxycarboxylate, methylphenoxycarboxylate). In certain embodiments, R_2 is chosen from H, Cl, Br, I, $-COOH$, $-COO^-$, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, tert-


butoxycarboxylate, phenoxy-carboxylate, and methylphenoxy-carboxylate. In certain embodiments, R_2 is chosen from H, Cl, Br, $-COOH$, and $-COO^-$. In certain embodiments, R_2 is H.

[0108] In certain embodiments, R_2 is $-C(O)OR_a$, where R_a is chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, alkynyl groups, substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R_2 is $-C(O)OR_a$, where R_a is chosen from hydrogen, alkyl groups, and substituted alkyl groups. In certain embodiments, R_2 is $-C(O)OR_a$, where R_a is chosen from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl. In certain embodiments, R_2 is $-C(O)OH$, $-C(O)OCH_3$, $-C(O)OCH_2CH_3$, $-C(O)OCH(CH_3)_2$, or $-C(O)OC(CH_3)_3$.


[0109] In certain embodiments, R_5 is chosen from halides, sulfonates, an azide, quaternary ammonium groups, and OR_a , where R_a is chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, alkynyl groups, substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R_5 is chosen from Cl, Br, and I. In certain embodiments, R_5 is Cl. In certain embodiments, R_5 is Br. In certain embodiments, R_5 is chosen from optionally substituted C_1 - C_6 alkanesulfonates and optionally substituted C_7 - C_{12} alkylbenzenesulfonates. In certain embodiments, R_4 is $-N\equiv N$. In certain embodiments, R_4 is Br.

In certain embodiments, R₅ is chosen from methanesulfonate, trifluoromethanesulfonate, and p-toluenesulfonate. In certain embodiments, R₅ is chosen from quaternary ammonium groups. In certain embodiments, R₅ is pyridinium or substituted pyridinium group.


[0110] In certain embodiments, the method comprises reacting a compound chosen from compounds having formula (ii) with a compound having formula (iii-a):




[0111] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-b):




[0112] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-c):




[0113] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-d):




[0114] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound chosen from compounds having formula (iii-e):




[0115] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-f):




[0116] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-g):




[0117] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-h):



[0118] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-i):




[0119] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-j):



iii-j.

[0120] In certain embodiments, the method comprises reacting a compound having formula (ii) with a compound having formula (iii-k):



iii-k.

[0121] In certain embodiments, the ratio of the compound having formula (iii) to the compound having formula (ii) is from about 0.1 to about 10. For example, the ratio is from about 0.5 to about 5, from about 0.8 to about 2.5, about 1, about 1.2, about 1.5, about 1.8, about 2, about 2.2, or about 2.5. In certain embodiments, the ratio is about 1.5.

[0122] In certain embodiments, the reaction comprises converting a compound of formula (ii) to a compound of formula (i) in the presence of a base. For example, the base can be an inorganic base or an organic base. In certain embodiments, the base comprises a base chosen from LiOH, NaOH, KOH, Na₂CO₃, NaHCO₃, K₂CO₃, KHCO₃, Na₃PO₄, Na₂HPO₄, NaH₂PO₄, K₃PO₄, K₂HPO₄, KH₂PO₄, LiOCH₃, NaOCH₃, KOCH₃, LiOCH₂CH₃, NaOCH₂CH₃, KOCH₂CH₃, LiOC(CH₃)₃, NaOC(CH₃)₃, KOC(CH₃)₃, ammonia, triethylamine (TEA), diisopropylethylamine (DIPEA), triethanolamine, imidazole,

benzimidazole, pyridine, histidine, tetramethylammonium hydroxide, or tetrabutylammonium hydroxide. In certain embodiments, the base comprises a base chosen from NaHCO_3 , KHCO_3 , Na_3PO_4 , Na_2HPO_4 , K_3PO_4 , K_2HPO_4 , $\text{LiOCH}_2\text{CH}_3$, $\text{NaOCH}_2\text{CH}_3$, KOCH_2CH_3 , $\text{LiOC}(\text{CH}_3)_3$, $\text{NaOC}(\text{CH}_3)_3$, $\text{KOC}(\text{CH}_3)_3$, triethylamine (TEA), diisopropylethylamine (DIPEA), and triethanolamine. In certain embodiments, the base comprises NaHCO_3 . In certain embodiments, the base comprises KHCO_3 . In certain embodiments, the base comprises Na_2HPO_4 . In certain embodiments, the base comprises K_2HPO_4 . In certain embodiments, the base comprises $\text{LiOC}(\text{CH}_3)_3$. In certain embodiments, the base comprises $\text{NaOC}(\text{CH}_3)_3$. In certain embodiments, the base comprises $\text{KOC}(\text{CH}_3)_3$. In certain embodiments, the base comprises triethylamine (TEA). In certain embodiments, the base comprises diisopropylethylamine (DIPEA). In certain embodiments, the base comprises triethanolamine.


[0123] In certain embodiments, the method comprises converting a compound chosen from compounds of formula (ii) to the dihydronaphthofuran derivative chosen from compounds of formula (i) in a solvent. In certain embodiments, the solvent is chosen from protic solvents or aprotic solvents. In certain embodiments, the solvent is chosen from water-miscible solvents. In certain embodiments, the solution comprises a solvent chosen from organic acids, alcohols, esters, amines, amides, aminoalcohols, ethers, sulfoxides, and heteroaromatics. In certain embodiments, the solution comprises a solvent chosen from acetone, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP), dimethylimidazolidinone (DMI), dimethylsulfoxide (DMSO), dioxane, methanol, ethanol, propanol, iso-propanol, pyridine, and tetrahydrofuran. In certain embodiments, the solution comprises a solvent

chosen from dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP), and dimethylsulfoxide (DMSO). In certain embodiments, the solution comprises acetonitrile. In certain embodiments, the solution comprises dimethylacetamide (DMA). In certain embodiments, the solution comprises dimethylformamide (DMF). In certain embodiments, the solution comprises N-methylpyrrolidone (NMP). In certain embodiments, the solution comprises dimethylsulfoxide (DMSO). In certain embodiments, the solution comprises dimethylimidazolidinone (DMI).

[0124] In certain embodiments, the solution comprises a water-immiscible solvent. For example, in certain embodiments, the solution comprises a solvent chosen from toluene, ether, tetrahydrofuran (THF), methyl-tert-butylether, methyl-tetrahydrofuran, ethyl formate, ethyl acetate, propyl acetate, isopropyl acetate, and t-butyl acetate.


[0125] In certain embodiments, the method comprises providing the compound chosen from compounds having formula (ii-c) and a base (e.g., diisopropylethylamine (DIPEA) in a solvent (e.g., dimethylformamide (DMF)). In certain embodiments, the method comprises heating the mixture. In certain embodiments, the mixture is heated to from about 30°C to about 70°C. In certain embodiments, the mixture is heated to about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, or about 70°C. In certain embodiments, the method comprises providing the nucleophile (iii-a).

[0126] In certain embodiments, the method comprises converting a compound having formula (iv):



salts and solvates thereof, to a compound chosen from compounds having formula (ii).

[0127] In certain embodiments, the method comprises reacting a 2-hydroxynaphthalene-1,4-dione compound having formula (iv) with a compound of formula (v):



where R_4 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, $C(=O)R_g$, $S(=O)_2R_e$, $P(=O)_2R_e$, $C(=O)OR_e$, $C(=O)NR_bR_c$, $S(=O)_2NR_bR_c$, and $P(=O)_2NR_bR_c$;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,

or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and


R_f and R_g each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

[0128] In certain embodiments, R_f is chosen from alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, alkynyl groups, substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R_f is chosen from alkyl groups and substituted alkyl groups. In certain embodiments, R_f is chosen from cycloalkyl groups and substituted cycloalkyl groups. In certain embodiments, R_f is chosen from aryl groups and substituted aryl groups. In certain embodiments, R_f is chosen from methyl, ethyl, isopropyl, tert-butyl, cyclohexyl, and phenyl. In certain embodiments R_f is ethyl.

[0129] In certain embodiments, R_4 is chosen from alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups,

substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R₄ is chosen from alkyl groups, cycloalkyl groups, heterocycle groups, and aryl groups. In certain embodiments, R₄ is chosen from methyl, ethyl, isopropyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridyl, and pyrrolyl. In certain embodiments, R₄ is chosen from phenyl, pyridyl, and pyrrolyl. In certain embodiments, R₄ is phenyl.

[0130] In certain embodiments, the compound of formula (v) is a compound of formula (v-a):




v-a.

[0131] In certain embodiments, the method comprises converting a 2-hydroxynaphthalene-1,4-dione chosen from compounds of formula (iv) to a compound of formula (ii) in a solvent. For example, the solvent can be chosen from toluene, 1,2-dichlorobenzene, xylene, anisole, acetone, acetonitrile, ethyl acetate, isopropyl acetate, dimethylformamide (DMF), N-methylpyrrolidone (NMP), dimethylimidazolidinone (DMI), dimethylsulfoxide (DMSO), dioxane, methanol, ethanol, propanol, iso-propanol, formic acid, acetic acid, propanoic acid, pyridine, and tetrahydrofuran. In certain embodiments, the solvent is chosen from 1,2-dichlorobenzene, xylene, anisole, dimethylformamide (DMF), N-methylpyrrolidone (NMP), dimethylimidazolidinone (DMI), and dimethylsulfoxide (DMSO).

[0132] In certain embodiments, the method comprises converting a compound of formula (iv) to a compound of formula (ii) at a temperature. For example, in certain embodiments, the temperature can be from about 40 °C to about 170 °C, from about 50 °C to about 150 °C, from about

60 °C to about 130 °C, or from about 70 °C to about 110 °C. In certain embodiments, the method comprises converting a compound of formula (iv) to a compound of formula (ii) at about 70 to about 75 °C, about 75 to about 80 °C, about 80 to about 85 °C, about 85 to about 90 °C, about 90 to about 95 °C, about 95 to about 100 °C, about 100 to about 105 °C, or about 105 to about 110 °C.

[0133] Another aspect of the present disclosure relates to methods of preparing a compound of formula (I):



prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.

[0134] In certain embodiments, one of the methods comprises providing a solution of a compound of formula (I). In certain embodiments, the solution of the compound of formula (I) comprises anisole. In certain embodiments, the ratio (e.g., the volume-to-mass ratio) of anisole to the compound of formula (I) is from about 1 to about 30, about 2 to about 25, about 5 to about 25, about 10 to about 20, about 5, about 8, about 10, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20.

[0135] In certain embodiments, the method comprises providing the solution of the compound formula (I) at a first temperature. In certain embodiments, the first temperature is not lower than about 70°C, about 80°C, about 90°C, about 100°C, about 105°C, about 110°C, about 115°C, about 120°C, about 130°C, about 140°C, or not lower than about 150°C. In certain embodiments, the first temperature


is about 100°C, about 105°C, about 110°C, about 115°C, about 120°C, or about 100°C to about 115°C.

[0136] In certain embodiments, the method comprises providing the solution of the compound of formula (I) at a second temperature. In certain embodiments, the second temperature is not higher than about 80°C, about 70°C, about 60°C, about 50°C, about 40°C, about 30°C, about 20°C, about 10°C, about 5°C, or not higher than about 0°C.

[0137] In certain embodiments, the second temperature is about 0°C. In certain embodiments, the second temperature is about 1°C. In certain embodiments, the second temperature is about 2°C, about 3°C, about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, about 9°C, about 10°C, about 11°C, about 12°C, about 13°C, about 14°C, or about 15°C. In certain embodiments, the second temperature is from about 0°C to about 5°C.

[0138] In certain embodiments, the method comprises providing the solution of the compound of formula (I) in the presence of a first agent. In certain embodiments, the first agent comprises silica gel. In certain embodiments, the ratio (e.g., the mass-to-mass ratio) of the first agent to the compound of formula (I) is from about 0.1 to about 10, about 0.2 to about 8, about 0.5 to about 5, about 0.5 to about 3, about 0.5 to about 2, about 0.5, about 0.8. In certain embodiments, the ratio of the first agent to the compound chosen from compounds of formula (I) is about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0.

[0139] Another aspect of the present disclosure relates to certain compounds that can be used to prepare compounds having formula (I). In certain embodiments, provided herein is a compound chosen from compounds having formula (i)



salts and solvates thereof,


wherein R_1 and R_2 each independently is a leaving group.

[0140] In certain embodiments, R_1 is selected from the group consisting of halides, OR_a , and NR_bR_c ; where R_a is selected from the group consisting of hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, alkynyl groups, substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and R_b and R_c each is independently selected from the group consisting of hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group. In certain embodiments, R_1 is selected from the group consisting of Cl, Br, I, OR_a , and NR_bR_c ; where R_a is selected from the group consisting of hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and R_b and R_c each is independently chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups. In certain embodiments, R_1 is selected from the

group consisting of Cl, Br, I, and NR_bH ; where R_b is selected from the group consisting of alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, aryl groups, and substituted aryl groups. In certain embodiments, R_1 is NR_bH , where R_b is phenyl or substituted phenyl.


[0141] In certain embodiments, R_2 is selected from the group consisting of halides, sulfonates (e.g., an optionally substituted C_1 - C_6 alkanesulfonate, such as methanesulfonate and trifluoromethanesulfonate, or an optionally substituted C_7 - C_{12} alkylbenzenesulfonate, such as p-toluenesulfonate), an azide, carboxylates (e.g., $-\text{COOH}$ or $-\text{COO}^-$), alkoxy-carboxylates (e.g., methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, or tert-butoxy-carboxylate), and aroxy-carboxylates (e.g., phenoxy-carboxylate, methylphenoxy-carboxylate). In certain embodiments, R_2 is selected from the group consisting of halides, carboxylates (e.g., $-\text{COOH}$ or $-\text{COO}^-$), alkoxy-carboxylates (e.g., methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, or tert-butoxy-carboxylate), and aroxy-carboxylates (e.g., phenoxy-carboxylate, methylphenoxy-carboxylate). In certain embodiments, R_2 is selected from the group consisting of Cl, Br, I, $-\text{COOH}$, $-\text{COO}^-$, methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, tert-butoxy-carboxylate, phenoxy-carboxylate, and methylphenoxy-carboxylate. In certain embodiments, R_2 is selected from the group consisting of Cl, Br, $-\text{COOH}$, $-\text{COO}^-$, methoxy-carboxylate, ethoxy-carboxylate, isopropoxy-carboxylate, and tert-butoxy-carboxylate. In certain embodiments, R_2 is tert-butoxy-carboxylate.

[0142] In certain embodiments, the compound of formula (i) conforms to formula (i-a)



salts and solvates thereof.


[0143] In certain embodiments, provided herein is a compound having formula (ii):



salts and solvates thereof;

wherein R₃ and X each is as defined herein.


[0144] In certain embodiments, provided herein is a compound chosen having formula (ii-a):



salts and solvates thereof,


wherein R₃ and R₄ each is as defined herein.

[0145] In certain embodiments, R₃ is hydrogen. In certain embodiments, provided herein is a compound having formula (ii-b):




salts and solvates thereof, wherein R_4 is as defined herein.

[0146] In certain embodiments, provided herein is a compound having formula (ii-c):



salts and solvates thereof.


[0147] In certain embodiments, provided herein is a compound having formula (ii-d):



salts and solvates thereof,


wherein R_2 and R_4 each is as defined herein.

[0148] In certain embodiments, provided herein is a compound having formula (ii-e):




salts and solvates thereof, wherein R_2 is as defined herein.

[0149] In certain embodiments, provided herein is a compound having formula (ii-f):




salts and solvates thereof, wherein R_3 is as defined herein.

[0150] In certain embodiments, provided herein is a compound having formula (ii-g):




salts and solvates thereof.

[0151] In certain embodiments, provided herein is a compound having formula (ii-h):




salts and solvates thereof, wherein R_2 is as defined herein.

[0152] In certain embodiments, provided herein is a compound having formula (ii-i):




salts and solvates thereof.

[0153] In certain embodiments, provided herein is a compound having formula (iii):




wherein R_2 and R_4 each is as defined herein.

[0154] In certain embodiments, provided herein is a compound chosen from compounds having formulae (iii-a) to (iii-k):




[0155] In certain embodiments, provided herein is a compound having formula (iv):




salts and solvates thereof.

[0156] In certain embodiments, provided herein is a compound having formula (v):



wherein R₄ and R_f each is as defined herein.


[0157] In certain embodiments, the compound having formula (v) conforms to formula v-a.



[0158] In certain embodiments, the present disclosure provides methods of preparing a compound of the present disclosure. In certain embodiments, the compound is prepared according to methods disclosed in PCT Patent Application Publication Numbers WO2009036099, WO2009036101, WO2011116398, and WO2011116399, which are each incorporated herein by reference in their entirety. In certain embodiments, a compound of the present disclosure is prepared by using the methods disclosed herein, together with synthetic methods known to one skilled in the art of organic synthesis, or variations thereof. In certain embodiments, a compound of the present disclosure is prepared by using methods known to one skilled in the art. It is understood that methods disclosed in WO2009036099, WO2009036101, WO2011116398, and WO2011116399, or herein, as well as those known to the skilled artisan, are for illustration purpose and, accordingly, do not in any way limit the scope of the appended claims.

[0159] Without being limited by any particular preparative methods, the present disclosure provides a method of preparing a compound of formula (I) of the present disclosure. In certain embodiments, the compound of formula (I) is prepared by a method shown in Scheme below, where R₁ and R₂ are as defined herein.


[0160] Scheme 1



[0161] As shown in Scheme 1, in certain embodiments, the method comprises reacting a compound having formula (i).


[0162] In certain embodiments, the compound of formula (I) is prepared by a method shown in Scheme 2 below.

[0163] Scheme 2




[0164] In certain embodiments, a compound chosen from compounds having formula (i) is prepared by a method shown in Scheme 3 below.

[0165] Scheme 3




[0166] In certain embodiments, a compound having formula (i-a) is prepared by a method shown in Scheme 4 below.

[0167] Scheme 4




[0168] In certain embodiments, a compound chosen from compounds having formula (ii) is prepared by a method shown in Scheme 5.

[0169] Scheme 5




[0170] In certain embodiments, the method comprises reacting a compound having formula (iv) with a compound having formula (v):



wherein R₄ and R_f each is as defined herein.

Examples

Example 1

[0171] Aniline (300 g, 3.22 mol) was added to a 1 L reactor containing triethyl orthoformate (790 mL, 1.5 eq) and HCl (0.01 eq, 10.68 mL 11% solution in methanol) at 23-31°C over 0.5 h. The reaction mixture was heated from 30°C to 120°C with stripping off ethanol over 3 hours. Ethanol stripping was stopped and the mixture was cooled to 35°C. Precipitation occurred. The mixture was heated back to 120°C. The pressure was slowly reduced and ethanol/triethyl orthoformate mixture was collected from 700 mbar. The product was collected from 36 mbar and approximately 100 ml residue remained in the reactor after distillation. The residue solidified at 50°C. The solid was dissolved in methanol. The main crop (295.9 g, NMR assay 102%) and additional crop (63 g, NMR assay 97%) of ethyl N-phenylformimidate (v-a) were obtained.

Example 2

[0172] Compound (iv) (2-hydroxy-1,4-naphthoquinone, "HNQ") (83 g, 477 mmol) was heated in 620 mL of anisole to 110°C. Ethyl N-phenylformimidate (v-a, 100 g, 1.4 equivalents) was added in one portion. The flask was rinsed with 30 mL of anisole and the rinse was added to reaction mixture. Internal temperature dropped to 106°C. Slight boiling and almost instantaneous formation of an orange precipitate was observed after mixture was heated back to 110°C. An exotherm was observed and the mixture was heated to 121°C. The reaction mixture was maintained at 120°C for 10 minutes and UPLC sample showed full conversion of HNQ at this point. The mixture was cooled to 22°C, and the resulting solid was filtered, rinsed with 250 mL of anisole and dried at 50°C/15 mbar for 16 h. A bright yellow, shiny, flaky solid (ii-c, 99.6 g, 75% yield, with UPLC purity 100%) was obtained.

[0173] B. Synthesis of Schiff base in anisole. HNQ at 90°C - (10.0 g, 56.3 mmol) was heated in 70 mL of anisole to 90°C under nitrogen atmosphere. Ethyl N-phenylformimidate (v-a, 2.7 g, 0.3 equivalents) was added dropwise over 15 minutes. Ethyl N-phenylformimidate (6.1 g, 0.7 eq) addition was continued over an hour. Crystallization started when about 0.5 eq. of ethyl-N-phenylformimidate was added. Full conversion of HNQ was observed 1 hour after completion of addition. Mixture was left to cool to room temperature over 2 hours. Schiff base (ii-c, 14.33 g, 90% yield, yellow solid, 100 % purity by UPLC) was obtained by filtering the mixture and the solids rinsed with 70 mL of anisole and dried at 50°C/15 mbar for 16 h.

[0174] C. Synthesis of Schiff base in anisole at 70 °C. Ethyl N-phenylformimidate (v-a, 9.42 g, 1.1 equivalents,

assay 98.8%) was added in one portion to HNQ (10.0g, 56.3mmol) and was heated in 70mL of anisole to 70 °C under nitrogen atmosphere. Crystallization started at 50 °C after 15 minutes. Full conversion of HNQ was observed 3 hours after completion of addition. Mixture was left to cool to room temperature over 2 hours. Schiff base was filtered, rinsed with 40 mL of anisole. Dried for 16 h at 50 °C at 15 mbar of pressure. Compound ii-c (15.19 g, 95 % yield, and 99.6% purity by UPLC) was obtained as a golden-yellow solid.

[0175] D. Synthesis of Schiff base in 1,2-dichlorobenzene. Compound (iv) (65 g, 373 mmol) was dissolved in 750 mL of 1,2- dichlorobenzene at 110°C. Ethyl N-phenyl formimidate (va) (85.4 g, 1.5 equivalents) was added over 10 minutes. A full conversion of compound (iv) was observed after 20 minutes at 110-140°C and 40 minutes at 140°C. The mixture was cooled to 55°C. Methylcyclohexane (100 mL) was added and the mixture was cooled to room temperature. The resulting solid was filtered off, washed with 300 mL of methylcyclohexane three times, and dried in a vacuum dryer at 15 mbar and 45°C for 16 h. The Schiff base (iia, 96.8 g) was obtained as a fluffy yellow solid with UPLC purity 100% and NMR assay 99.1%. The yield corrected according to the NMR assay was determined to be 93%.

[0176] Synthesis of Schiff base in DMF. HNQ (iv, 5 g, 28.7 mmol) was heated in 50 mL of DMF to 110°C. Ethyl N-phenylformimidate (v-a, 6.42 g, 1.5eq) was added dropwise. No boiling was observed at this point. The mixture was heated to 118°C and formation of a dark solid was observed. The mixture was stirred for 5 minutes and a sample was obtained for UPLC analysis, which showed full conversion of HNQ. After cooling to 18°C, the mixture was filtered and

the solid was rinsed with 120 mL of DMF, 60 mL of iPrOH and then dried in a vacuum chamber at 50°C/15 mbar for 17 h. The Schiff base (ii-c, 6.38 g, UPLC purity 100% by area) was obtained as a fluffy yellow solid. Reaction yield calculated by weight was determined to be 80%.

Example 3

[0177] DMF (40 mL) was added to Schiff base (ii-c, 10 g, 36.1 mmol) and micronized NaHCO₃ (12.12 g, 4 eq.). The mixture was heated to 44°C and crude BrAA (iii-a, 12.83 g, 1.4 eq.) was added in one portion. The mixture was maintained at 45-50°C. 0.2% of unreacted Schiff base (ii-c) was detected in reaction mixture after 3 h. The mixture was filtered and the collected solids were washed with 15 mL of DMF. The crude compound (i-a, 71.41 g, yield 83%) solution was obtained.

Example 4

[0178] The crude compound (i-a) crude solution (337.3 g) in DMF was concentrated to 166.3 g (Ti=50°C/19 mbar, reduced by 50%). A minor amount of white mineral salt precipitation was observed. The concentrated mixture (including precipitated mineral salt) was added to 340 mL of sulfuric acid/acetic acid (1:1) mixture over 1h at 18-22°C. Gas emission was observed. Formation of a yellow precipitate was observed after ~3/4 of the mixture was added. The resulting solid was filtered off, the slurry was washed on filter with 500 mL of water and then with 250 mL of iPrOH, and then solid was dried at 50°C/15 mbar for 18 h. A mustard-yellow powder (24.3 g, 99.6% by area, 97% isolated yield corrected to NMR assay) was obtained.

Example 5a

[0179] 2-Hydroxynaphthalene-1,4-dione (iv, 5 g, 28.7 mmol) was dissolved in 50 mL of DMI at 80-90°C. The solution was heated to 140°C. Ethyl N-phenylformimidate (va, 6.62 g, 1.5 eq) was added slowly to the heated solution. A full conversion of 2-hydroxynaphthalene-1,4-dione (iv) and formation of fine precipitate was observed after 15 minutes.

[0180] The mixture was cooled to 45°C. A thick slurry was formed (black solution and yellow precipitate). This slurry was used in the next step without any purification.

Example 5b

[0181] DMI (20 mL), NaHCO₃ (14.11 g, 6 eq), and tert-butyl-2-bromo-acetoacetate (iii-a) (12.46 g, 1.5 eq) were added to the crude Schiff base (ii-c) mixture in DMI at 45°C. A full conversion of Schiff base (ii-c) was observed after 6 h at 45-50°C.

[0182] The inorganic salt was filtered off and rinsed with 20 mL of DMI. The yield over two steps corrected according to the NMR assay was 57%. The filtrate containing the dihydronaphthofuran derivative (i-a) was used in the next step without any further purification.

Example 5c

[0183] Acetic acid (100 mL) and sulfuric acid (100 mL) were mixed and cooled to 20°C in a water bath. The filtrate from the previous step (Example 5b, 100 g, 6.86% solution in DMI) was added dropwise to the mixture over 1.5 h at 18-24°C. A black, clear, and thick solution was observed.

[0184] The resulting mixture was poured into ice/water mixture (300 mL) at 0-15°C and slowly stirred for 45 minutes. A very fine precipitate was filtered off, rinsed

with water, and dried in vacuum chamber at 50°C/15 mbar for 15 h. A brown precipitate (compound (I), 3.95 g) was obtained. Assay by NMR 68.1%. Step 3 yield corrected to NMR assay was 71%.

[0185] The isolated yield from 2-hydroxynaphthalene-1,4-dione (iv) corrected to NMR assay was 39%. With the isolated Schiff base (ii-c) and alkylation in DMF, the isolated yield of crude compound (I) over three steps was 71%.

Example 6

[0186] Compound (I) (200 g, 1 X, crude-1) and silica gel (1.3 X, 100-200 mesh) were charged into a reactor and then anisole (15 V) was added. The reaction mixture was heated to 100-110°C and stirred for 1-2 h. The reaction mixture was then cooled to 80°C, and filtered through 0.5~1.0X of diatomite. The solids were combined with anisole (3 V) at 80-90°C and then filtered. The combined filtrate was heated to 80-90°C and then slowly cooled to 0-5°C. The solids were filtered and dried at 50-60°C under vacuum to give compound (I) (crude-2). The crude-2 was triturated in hot EtOAc (25 V) to give compound (I) (75% yield form crude-1).


[0187] Compound (I) (3 g, crude, assay 91.5%) was combined with anisole (90 mL, 30 vol) at 100-110°C. Activated carbon (100 mesh, 40% w/w) was added and the mixture was stirred for 1 h. The carbon was filtered hot through a carton-board lined glass filter and washed with 20 mL of hot anisole. The resulting filtrate was concentrated to ~13 vol at 70°C/30 mbar. The resulting mixture was reheated to 110°C and was then cooled to 0°C over 2 h. After cooling, the mixture was filtered and the collected solids were rinsed with 20 mL of cold anisole and dried in vacuum chamber at 50°C/15 mbar for 18 h. 2.4g of

Fine, orange-yellow needles (compound (I), 2.4 g) were obtained. UPLC purity was determined to be 100% by area. The purity was determined by the NMR assay to be 99.1% and the yield was determined to be 87%.

[0188] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the present disclosure described herein. Such equivalents are intended to be encompassed by the following claims.


What Is Claimed:

1. A method of making a compound having formula (I):



a prodrug, a pharmaceutically acceptable salt, or a solvate of any of the foregoing;

comprising reacting a compound having formula (i):



or a salt or solvate thereof, with an acid;

wherein R_1 and R_2 each independently is a leaving group.

2. The method of claim 1, wherein

R_1 is chosen from halides, OR_a , and NR_bR_c ; where R_a is chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, alkynyl groups, substituted alkynyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_b and R_c each is independently chosen from hydrogen, alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or

R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group.


3. The method of claim 1 or claim 2, wherein R₁ is NR_bH, where R_b is phenyl or substituted phenyl.

4. The method of any one of claims 1 to 3, wherein R₂ is chosen from halides, carboxylates, alkoxy-carboxylates, and aryloxy-carboxylates.

5. The method of any one of claims 1 to 4, wherein R₂ is chosen from Cl, Br, -COOH, -COO⁻, methoxycarboxylate, ethoxycarboxylate, isopropoxycarboxylate, and tert-butoxycarboxylate.


6. The method of any one of claims 1 to 5, wherein R₂ is tert-butoxycarboxylate.

7. The method of any one of claims 1 to 6, wherein the compound having formula (i) has formula (i-a):



or a salt or solvate thereof.

8. The method of any one of claims 1 to 7, further comprising reacting a compound having formula (ii):



ii

or a salt or solvate thereof;

wherein

X is O or N-R₄, and

R₃ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups;

R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, C(=O)R_g, S(=O)₂R_e, P(=O)₂R_e, C(=O)OR_e, C(=O)NR_bR_c, S(=O)₂NR_bR_c, and P(=O)₂NR_bR_c;


wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,

or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

R_e is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and


R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups

with a compound having formula (iii):



wherein R₂ and R₅ each independently is a leaving group.


9. The method of claim 8, wherein the compound having formula (ii) has the formula (ii-b)



wherein R₄ is chosen from methyl, ethyl, isopropyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridyl, and pyrrolyl.

10. The method of claim 8 or claim 9, wherein R₄ is phenyl.


11. The method of any one of claims 8 to 10, wherein the compound having formula (ii) has formula (ii-c):



ii-c


or a salt or solvate thereof.

12. The method of claim 11, wherein the compound having formula (iii) has the formula (iii-a):



iii-a.

13. The method of any one of claims 1 to 12, further comprising converting a 2-hydroxynaphthalene-1,4-dione having formula (iv):



iv

or a salt or solvate thereof, to the compound having formula (ii).

14. The method of claim 1, wherein the acid comprises an acid chosen from sulfuric acid (H_2SO_4), phosphoric acid (H_3PO_4), nitric acid (HNO_3), perchloric acid ($HClO_4$), hydrofluoric acid (HF), hydrochloric acid (HCl), hydrobromic acid (HBr), and hydroiodic acid (HI).

15. The method of claim 1, wherein the acid is sulfuric acid (H_2SO_4), phosphoric acid (H_3PO_4), or hydrochloric acid (HCl).

16. The method of claim 1, wherein the acid is chosen from formic acid, acetic acid, acetic anhydride, trifluoroacetic acid, trifluoroacetic anhydride, chloroacetic acid, and chloroacetic anhydride.

17. The method of claim 1, wherein the acid comprises an acid chosen from sulfuric acid (H_2SO_4), acetic acid, and acetic anhydride.


18. The method of any one of claims 1 and 14 to 17, comprising reacting a solution of the compound having formula (i) with the acid.

19. The method of claim 18, wherein the solution comprises a solvent chosen from isopropyl acetate, dimethylformamide (DMF), N-methylpyrrolidone (NMP), and dimethylimidazolidinone (DMI).

20. The method of any one of claims 8 to 13, comprising reacting the compound having formula (ii) in the presence of a base chosen from $NaHCO_3$, $KHCO_3$, Na_3PO_4 , Na_2HPO_4 , K_3PO_4 , K_2HPO_4 , $LiOCH_2CH_3$, $NaOCH_2CH_3$, $KOCH_2CH_3$, $LiOC(CH_3)_3$, $NaOC(CH_3)_3$,

KOC(CH₃)₃, triethylamine (TEA), diisopropylethylamine (DIPEA), and triethanolamine.

21. The method of claim 14, comprising reacting the 2-hydroxynaphthalene-1,4-dione having formula (iv) with a compound of formula (v):



(v)

wherein R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, C(=O)R_g, S(=O)₂Re, P(=O)₂Re, C(=O)OR_e, C(=O)NR_bR_c, S(=O)₂NR_bR_c, and P(=O)₂NR_bR_c;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups,

or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;


Re is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups,

alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_f and R_g each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

22. The method of claim 21, wherein R_f is chosen from methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl.

23. A compound having formula (ii):



ii,

or a salt or solvate thereof;

wherein R_3 is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, and

X is O or N-R₄;

wherein R₄ is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, substituted aryl groups, C(=O)R_g, S(=O)₂Re, P(=O)₂Re, C(=O)OR_e, C(=O)NR_bR_c, S(=O)₂NR_bR_c, and P(=O)₂NR_bR_c;

wherein R_b and R_c each independently is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups, or R_b and R_c together with the N to which they are bonded form a heterocycle group or a substituted heterocycle group;

Re is chosen from alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups; and

R_g is chosen from hydrogen, alkyl groups, substituted alkyl groups, alkenyl groups, substituted alkenyl groups, alkynyl groups, substituted alkynyl groups, cycloalkyl groups, substituted cycloalkyl groups, heterocycle groups, substituted heterocycle groups, aryl groups, and substituted aryl groups.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/063734

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D307/92 C07C251/16
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07D
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATIL SHARAD R ET AL: "NIR-emitting quinone-fused coumarin dyes: aqueous mediated, catalyst free synthesis and their optical properties", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 57, no. 29, 2 June 2016 (2016-06-02), pages 3100-3104, XP029623425, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2016.06.003 compound 2	23
Y	WO 2009/036099 A1 (BOSTON BIOMEDICAL INC [US]; LI CHIANG JIA [US]; JIANG ZHIWEI [US]; ROG) 19 March 2009 (2009-03-19) cited in the application page 49; example 8	1-22
	----- -/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 16 January 2018	Date of mailing of the international search report 25/01/2018
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Gettins, Marc

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/063734

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LEE Y R ET AL: "Ceric Ammonium Nitrate (CAN)-Mediated Oxidative Cycloaddition of 1,3-Dicarbonyls to Conjugated Compounds. Efficient Synthesis of Dihydrofurans, Dihydrofurocoumarins, Dihydrofuroquinolinones, Dihydrofurophenalenones, and Furonaphthoquinone Natural Products", TETRAHE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 45, 3 November 2000 (2000-11-03), pages 8845-8853, XP004238537, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(00)00839-5 Scheme 1, conversion of 40 to 37; page 8849</p> <p>-----</p>	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/063734

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 2009036099	A1	19-03-2009	CA 2736532 A1	19-03-2009
			CA 2736563 A1	19-03-2009
			CA 2736564 A1	19-03-2009
			CA 2911990 A1	19-03-2009
			CN 101854802 A	06-10-2010
			CN 101854930 A	06-10-2010
			CN 101854937 A	06-10-2010
			CN 103288787 A	11-09-2013
			CN 104586832 A	06-05-2015
			CN 105963289 A	28-09-2016
			CY 1117604 T1	26-04-2017
			CY 1117833 T1	17-05-2017
			CY 1118476 T1	12-07-2017
			DK 2190429 T3	30-05-2016
			DK 2194987 T3	15-08-2016
			DK 2200431 T3	15-08-2016
			EP 2190429 A1	02-06-2010
			EP 2194987 A2	16-06-2010
			EP 2200431 A1	30-06-2010
			EP 3050566 A2	03-08-2016
			EP 3058941 A1	24-08-2016
			EP 3067054 A1	14-09-2016
			ES 2569215 T3	09-05-2016
			ES 2583010 T3	16-09-2016
			ES 2584904 T3	30-09-2016
			HK 1148906 A1	05-02-2016
			HK 1148942 A1	13-01-2017
			HK 1148943 A1	15-11-2013
			HR P20160430 T1	20-05-2016
			HR P20160625 T1	12-08-2016
			HR P20160949 T1	07-10-2016
			HU E027443 T2	28-10-2016
			HU E027657 T2	28-11-2016
			HU E029111 T2	28-02-2017
			JP 5688840 B2	25-03-2015
			JP 5701603 B2	15-04-2015
			JP 5872160 B2	01-03-2016
			JP 5925849 B2	25-05-2016
			JP 5938072 B2	22-06-2016
			JP 6106149 B2	29-03-2017
			JP 2010539095 A	16-12-2010
			JP 2010539097 A	16-12-2010
			JP 2010539098 A	16-12-2010
			JP 2014221843 A	27-11-2014
			JP 2014231522 A	11-12-2014
			JP 2015034179 A	19-02-2015
			JP 2015038151 A	26-02-2015
			JP 2016034976 A	17-03-2016
			JP 2016065101 A	28-04-2016
			JP 2016094465 A	26-05-2016
			JP 2016147906 A	18-08-2016
			PL 2190429 T3	30-09-2016
			PL 2194987 T3	31-01-2017
			PL 2200431 T3	31-01-2017
			PT 2194987 T	05-08-2016
			PT 2200431 T	03-08-2016
			US 2010310503 A1	09-12-2010
			US 2011112180 A1	12-05-2011

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/063734

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2012252763 A1	04-10-2012
		US 2015018410 A1	15-01-2015
		US 2017197932 A1	13-07-2017
		WO 2009036059 A2	19-03-2009
		WO 2009036099 A1	19-03-2009
		WO 2009036101 A1	19-03-2009
<hr/>			